Tonix Pharmaceuticals Holding Corp.TNXPReports Mon, Nov 9 · Third Quarter 2026
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · tonixpharma.com
Tonix Pharmaceuticals is a biopharmaceutical company developing and commercializing therapeutics for central nervous system, immunology and infectious disease indications, including its approved fibromyalgia product and a portfolio of clinical-stage candidates.
Key ratios
FCF / Sales
-543.3%TTM
2025
-787.5%2024
-604.8%2023
-1414.7%
ROA
-46.8%TTM
2025
-35.7%2024
-30.6%2023
-38.9%
ROE
-81.8%TTM
2025
-64.5%2024
-106.1%2023
-74.6%
Revenue growth
196.0%TTM
2025
29.9%2024
29.9%
Recent news
Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation
Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA
Track TNXP in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer